Therapeutic targeting of the oncogenic Wnt signaling pathway for treating colorectal cancer and other colonic disorders
- PMID: 33346022
- DOI: 10.1016/j.addr.2020.12.010
Therapeutic targeting of the oncogenic Wnt signaling pathway for treating colorectal cancer and other colonic disorders
Abstract
The canonical Wnt pathway is one of the key cellular signaling cascades that regulates, via the transcriptional co-activator β-catenin, numerous embryogenic developmental processes, as well as tissue homeostasis. It is therefore not surprising that misregulation of the Wnt/β-catenin pathway has been implicated in carcinogenesis. Aberrant Wnt signaling has been reported in a variety of malignancies, and its role in both hereditary and sporadic colorectal cancer (CRC), has been the subject of intensive study. Interestingly, the vast majority of colorectal tumors harbor mutations in the tumor suppressor gene adenomatous polyposis coli (APC). The Wnt pathway is complex, and despite decades of research, the mechanisms that underlie its functions are not completely known. Thus, although the Wnt cascade is an attractive target for therapeutic intervention against CRC, one of the malignancies with the highest morbidity and mortality rates, achieving efficacy and safety is yet extremely challenging. Here, we review the current knowledge of the Wnt different epistatic signaling components and the mechanism/s by which the signal is transduced in both health and disease, focusing on CRC. We address some of the important questions in the field and describe various therapeutic strategies designed to combat unregulated Wnt signaling, the development of targeted therapy approaches and the emerging challenges that are associated with these advanced methods.
Keywords: Colonic delivery; Colorectal cancer; Wnt signalling.
Copyright © 2020 Elsevier B.V. All rights reserved.
Similar articles
-
Therapeutic potential of targeting the Wnt/β-catenin signaling pathway in colorectal cancer.Biomed Pharmacother. 2019 Feb;110:473-481. doi: 10.1016/j.biopha.2018.11.082. Epub 2018 Dec 6. Biomed Pharmacother. 2019. PMID: 30530050 Review.
-
Wnt-driven LARGE2 mediates laminin-adhesive O-glycosylation in human colonic epithelial cells and colorectal cancer.Cell Commun Signal. 2020 Jun 25;18(1):102. doi: 10.1186/s12964-020-00561-6. Cell Commun Signal. 2020. PMID: 32586342 Free PMC article.
-
miR-155 Is Downregulated in Familial Adenomatous Polyposis and Modulates WNT Signaling by Targeting AXIN1 and TCF4.Mol Cancer Res. 2018 Dec;16(12):1965-1976. doi: 10.1158/1541-7786.MCR-18-0115. Epub 2018 Aug 2. Mol Cancer Res. 2018. PMID: 30072583
-
MicroRNA-494 promotes cancer progression and targets adenomatous polyposis coli in colorectal cancer.Mol Cancer. 2018 Jan 5;17(1):1. doi: 10.1186/s12943-017-0753-1. Mol Cancer. 2018. PMID: 29304823 Free PMC article.
-
Transcriptional Regulation of Wnt/β-Catenin Pathway in Colorectal Cancer.Cells. 2020 Sep 19;9(9):2125. doi: 10.3390/cells9092125. Cells. 2020. PMID: 32961708 Free PMC article. Review.
Cited by
-
PGM3 regulates beta-catenin activity to promote colorectal cancer cell progression.Exp Biol Med (Maywood). 2022 Sep;247(17):1518-1528. doi: 10.1177/15353702221101810. Epub 2022 Jun 20. Exp Biol Med (Maywood). 2022. PMID: 35723049 Free PMC article.
-
Pan-cancer analysis combined with experiments predicts CTHRC1 as a therapeutic target for human cancers.Cancer Cell Int. 2021 Oct 26;21(1):566. doi: 10.1186/s12935-021-02266-3. Cancer Cell Int. 2021. PMID: 34702252 Free PMC article.
-
Epigenomic analysis reveals a unique DNA methylation program of metastasis-competent circulating tumor cells in colorectal cancer.Sci Rep. 2023 Sep 16;13(1):15401. doi: 10.1038/s41598-023-42037-w. Sci Rep. 2023. PMID: 37717096 Free PMC article.
-
Nanoparticle-Based RNAi Therapeutics Targeting Cancer Stem Cells: Update and Prospective.Pharmaceutics. 2021 Dec 8;13(12):2116. doi: 10.3390/pharmaceutics13122116. Pharmaceutics. 2021. PMID: 34959397 Free PMC article. Review.
-
Multivalent Interaction of Beta-Catenin With its Intrinsically Disordered Binding Partner Adenomatous Polyposis Coli.Front Mol Biosci. 2022 Jun 8;9:896493. doi: 10.3389/fmolb.2022.896493. eCollection 2022. Front Mol Biosci. 2022. PMID: 35755812 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical